HEC-88473 Drug Asset Due Diligence Report 2026

This HEC-88473 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether HEC-88473 can convert its Fc fusion protein profile and FGF21R x GLP-1R biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	HEC-88473 (query alias: HEC-88473)
Modality / target	Fc fusion protein; FGF21R x GLP-1R; FGF21R agonists, GLP-1R agonists
Highest global status	Phase 2
Originator	Dongguan HEC Biopharmaceutical R&D Co., Ltd.
Active developers	Sunshine Lake Pharma Co., Ltd.

The MCP disease footprint includes Diabetes Mellitus, Type 2, Metabolic Dysfunction Associated Steatohepatitis, Obesity. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07616037	Phase 2	Recruiting	30	Primary endpoint not disclosed in English source
NCT06148649	Phase 2	Completed	234	Primary endpoint not disclosed in English source
NCT05943886	Phase 1	Completed	164	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: A randomized, double-blind, placebo-controlled study

Phase 1/2; n=not disclosed; evaluation: Positive. Reported fields: Adverse Event: gastrointestinal disorders = 29, 48.3% ; Adverse Event: gastrointestinal disorders = 29, 48.3%

First-in-Human Study on Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of HEC88473, a Novel Dual GLP-1 and FGF21 Receptor Agonist in Healthy and Obese Chinese Subjects

Phase 1; n=not disclosed; evaluation: Positive. Reported fields: Adverse Event: gastrointestinal disorders = the majority of treatment-related adverse events being gastrointestinal disorders of mild severity ; Adverse Event: gastrointestinal disorders = the majority of treatment-related adverse events being gastrointestinal disorders of mild severity

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

HEC-88473 addresses Diabetes Mellitus, Type 2, Metabolic Dysfunction Associated Steatohepatitis, Obesity. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Fc fusion protein—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 1 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2024-11-12	Apollo Therapeutics Signs Exclusive Ex-China License From Sunshine Lake Pharma for Clinical-Stage FGF21 / GLP-1 Dual Receptor Agonist, a Therapeutic With Major Commercial Potential in Multiple Indications	Phase 2	US$12.0M upfront; US$926.0M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Combination of GLP-1r/GIPR dual agonist and FGF21 compound and use”. The milestone feed surfaced a patent-application signal described as “Combined medicine for preventing and/or treating obesity”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Clinical differentiation versus current standards and pipeline competitors
Safety, dose optimization, and long-term tolerability
Patent scope, territorial rights, manufacturing, and commercial positioning

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO